Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p by Liu, Zihao et al.
Liu et al. Cell Death and Disease           (2019) 10:55 
https://doi.org/10.1038/s41419-018-1287-1 Cell Death & Disease
ART ICLE Open Ac ce s s
Circular RNA hsa_circ_001783 regulates
breast cancer progression via sponging
miR-200c-3p
Zihao Liu1, You Zhou 2, Gehao Liang1, Yun Ling1, Weige Tan3, Luyuan Tan1, Robert Andrews2, Wenjing Zhong1,
Xuanxuan Zhang1, Erwei Song1,3 and Chang Gong1
Abstract
Increasing evidence suggests circular RNAs (circRNAs) exert critical functions in tumor progression via sponging
miRNAs (microRNAs). However, the role of circRNAs in breast cancer remains unclear. Here we systematically analyzed
the circular RNAs in breast cancer based on their characteristic in sponging disease-speciﬁc miRNAs and identiﬁed
hsa_circ_001783 as a top ranked circRNA in our computation and veriﬁed its high expression in both breast cancer
cells and cancer tissue. A higher level of hsa_circ_001783 was signiﬁcantly correlated with heavier tumor burden and
poorer prognosis of patients with breast cancer. Knockdown of this circRNA remarkably inhibited the proliferation and
invasion of breast cancer cells. Importantly, hsa_circ_001783 promoted progression of breast cancer cells via sponging
miR-200c-3p. Taken together, hsa_circ_001783 may serve as a novel prognostic and therapeutic target for breast
cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer
for women in the world1,2. Despite recent advances in
early diagnosis and effective treatment, breast cancer in
some patients would progress to metastatic stage after
therapy without knowing the reason. Therefore, it is
essential to search for novel molecules in order to
understand the progression of breast cancer.
Circular RNAs (circRNAs) were ﬁrst detected in virus as
covalently closed looped RNAs3. As next-generation
sequencing technologies are developing rapidly, a num-
ber of circRNAs have been identiﬁed as functional
molecules in regulating disease progression rather than
splicing by-products4–6. Our previous study has demon-
strated that circRNAs can promote breast cancer cells
progression under hypoxia7. Others have revealed cir-
cRNAs contribute to breast cancer proliferation and
invasion7–9. Further studies indicate that imperfect mat-
ches could be formed in circRNA-miRNA duplex, which
enable circRNAs to serve as “miRNA sponge” and prevent
miRNA-mediated degradation of mRNAs10. For example,
CDR1as sponges miR-7 via its miR-7 targeting sites and
regulates tumor progression11,12. CircHIPK3, circGFRA1,
and hsa_circ_0001982 have been reported as functional
miRNA sponges in cancers8,9,13. These studies focused on
the differentially expressed circRNAs rather than eluci-
dating their sponge ability and the role of circRNAs in
breast cancer remains obscure. Thus, there is an urgent
need to characterize their sponge abilities and deﬁne the
associated molecular mechanism in breast cancer.
In the present study, we proposed a new bioinformatics
method to screen “circular sponges”. We used ﬁve algo-
rithms to predict binding sites of human miRNAs to the
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conserved sequences of individual circRNAs. Simulta-
neously, we identiﬁed breast cancer-associated miRNAs
using Ingenuity knowledge database, Pubmed, and
Embase. Five essential functional features were used to
score the strength associations between miRNAs and
breast cancer. And the network branches across circRNA,
miRNA, and breast cancer were ranked. We further assess
the clinical potential and explore the molecular function
of the top ranked circRNA in breast cancer.
Material and methods
Data extraction and analysis
CircRNA annotations and sequences were extracted from
circBase14. MiRNA sequences were extracted from miR-
Base15. The conserved circRNA sequences were analyzed
as described16. Five algorithms including Targetscan17,
miRanda18, PITA19, RNAhybrid20, and RNA22 (ref. 21) were
used to analyze the potential bindings of miRNAs to indi-
vidual circRNA. The potential targets of individual miRNAs
were predicted by starbase with summation of targetScan
sites, picTar sites, RNA22 sites, PITA sites, and miRanda
sites ≥5 (ref. 22). Two miRNA microarray datasets
(GSE40056 and GSE28969) and one mRNA microarray
dataset (GSE41313) were downloaded from NCBI GEO
public database (www.ncbi.nlm.nih.gov/geo) and analyzed
by R version 3.4.3. The log2FC > 1.5 and P < 0.05 were
characterized as differentially expressed miRNAs or
mRNAs. The circRNA–miRNA–mRNA was visualized by
Cytoscape (version 3.6.0). The miRNA gene ontology (GO)
terms “biological process” analysis was constructed by
Cytoscape plug-in ClueGo23. The mRNA GO terms were
analyzed by DAVID (https://david.ncifcrf.gov/).
Patient samples and clinical database
A total of 136 breast cancer patients aged from 18 to 70
years old enrolled Sun Yat-sen Memorial Hospital
(SYSMH) between 1 June 2010 and 31 May 2015. Their
parafﬁn-embedded tissue samples and paired non-
tumorigenesis tissue samples (n= 18) were collected for
RNA ﬂuorescence in situ hybridization (FISH). Patients
who received neoadjuvant chemotherapy were excluded.
All the HER2 (human epidermal growth factor receptor
2)-positive patients received anti-HER2 therapy. In addi-
tion, a total of 50 fresh-frozen cancer specimens were
collected from breast cancer patients who received no
therapy before surgery at the Breast Tumor Center of
SYSMH. The specimens were stored in RNA later
(Ambion, USA) at −80 °C immediately and were used for
qPCR analysis afterwards.
RNA FISH
Cy3-labeled oligonucleotide probe for hsa_circ_001783
and FAM-labeled oligonucleotide probe for hsa-miR-
200c-3p were applied for RNA FISH. The oligonucleotide
sequences are available in the Supplementary Informa-
tion. Parafﬁn section of breast cancer samples were
deparafﬁnized with 100% xylene and rehydrated with
different graded ethanol. For RNA FISH of co-localization
of hsa_circ_001783 and hsa-miR-200c-3p, cells were
seeded in a glass-bottom dish. Then they were incubated
with prehybridization solution at 37 °C for 30min and the
probes (Ribobio, China, 20 μM) were added to slides or
dish individually and hybridized overnight. Then they
were washed with buffer I (4× SSC, 0.1% Tween-20) for
three times, wash with buffer II (2 × SSC) for once, and
wash with buffer III (1× SSC) for once. After being
washed with phosphate-buffered saline, they were incu-
bated with DAPI to stain cell nuclear. The cells at each
staining intensity were recorded on a scale of 0 (no
staining), 1 (light red), 2 (red), 3 (strong red), and 4 (dark
red). The staining index (SI) was calculated as follows:
SI= staining intensity × proportion of positively stained
cells. Positive cells in the whole ﬁelds of view were
calculated.
RNA-binding protein immunoprecipitation (RIP)
The RIP assay was performed by Magna RIP Kit (Mil-
lipore, USA) and was conducted as previously instruc-
ted13. Brieﬂy, 1 × 107 cells of HEK-293T were incubated
with lysis buffer with protease and RNase inhibitors
added. Then the cell lysis was incubated with magnetic
beads which are conjugated with human ani-Argonaute2
(AGO2) antibody (Millipore, USA) or negative control
IgG (Millipore, USA), respectively, at 4 °C overnight.
Subsequently, samples were washed and incubated with
Proteinase K. Immunoprecipitated RNA was puriﬁed and
was subjected to quantitative real-time PCR analysis to
determine hsa_circ_001783.
CircRNA pull-down
Biotin-labeled hsa_circ_001783 probe and control probe
(Sangon Biotech, China) were used for circRNA pull-down
and the assay was performed as mentioned previously24–26.
In brief, MDA-MB-468 was cross-linked by 1%
formaldehyde for 30min, lysed in co-IP buffer, and
centrifugated. The supernatant was incubated with
hsa_circ_001783-speciﬁc probes-streptavidin beads (Life
Technologies, USA) mixture overnight at 37 °C. On the
next day, the samples were washed and incubated with lysis
buffer and proteinase K. Finally, the mixture was added with
TRIzol reagent for RNA extraction and followed by detec-
tion of hsa_circ_001783, hsa-miR-200c-3p, and β-actin.
AGO-binding sites from PAR-CLIP data sets
The AGO1 and AGO2 binding sites were acquired
from published photoactivatable cross-linking immu-
noprecipitation (PAR-CLIP) data in GEO database
(https://www.ncbi.nlm.nih.gov/geo/). Three PAR-CLIP
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datasets (GSE28865, GSE43573, and GSE21918) from
HEK293 cells were extracted. We analyzed the AGO1 as
well as AGO2 binding sites of hsa_circ_001783 genomic
region.
Cell lines and treatment
The human non-carcinogenesis mammary epithelial cell
line (MCF-10A) and human breast tumor cell lines T47D,
BT474, SK-BR-3, MCF-7, MAD-MB-468, and MDA-MB-
231 were obtained from American Type Culture Collec-
tion (ATCC). All cell lines which were passaged less than
6 months were authenticated by short tandem repeat DNA
proﬁling within 6 months and were cultured according to
the recommended protocols. MDA-MB-231 and MDA-
MB-468 were transfected with small interfering RNA and
miR-200c-3p inhibitor (GenePharma, China) using Lipo-
fectamineTM 3000 (Invitrogen, MA, USA).
Luciferase report assay
The conserved sequences of hsa_circ_001783 were
cloned into pGL3-enhancer vector between BgIII and
SamI sites. 3 × 104 cells of MDA-MB-231 and MDA-MB-
468 were seeded in a 24-well plate individually and co-
transfected with 300 ng pGL3-has_circ_001783 as well as
pGL3 control vector. Subsequently, cells were transfected
with mimics negative control, inhibitor control, hsa-miR-
200c-3p mimics, or inhibitor respectively. After 24 h of
transfection, the luciferase assay was conducted using
dual luciferase reporter assay (Vazyme, China) according
to the manufacturer’s instructions.
Statistical analysis
Pearson chi-square test or Fisher’s exact test was per-
formed for categorical values. Mann–Whitney U test and
Kruskal–Wallis test were used to determine the differ-
ences between groups. Mann–Whitney U test was applied
to evaluate the association between has_circ_001783 levels
and various clinical pathological variables in breast cancer
patients. Pearson’s correlation coefﬁcient analysis was used
to assess the linear correlations. Survival rates and curves
were determined by the Kaplan–Meier method, and the
comparison of survival differences was evaluated by using
the log-rank test. COX regression analysis was used for
univariate and multivariate analysis of correlation between
clinical pathological variables and survival. All data sta-
tistical analyses were performed using Graphpad Prism
version 6.0 (GraphPad Software Inc., San Diego, CA, USA)
and SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). In all
cases, P values less than 0.05 were considered statistically
signiﬁcant. All statistical tests were two-sided.
Additional experiment procedures
Colony formation assay, migration and invasion
assay, immunohistochemistry, CCK8 assay, EdU assay,
nuclear–cytoplasmic fraction assay are provided in Sup-
plementary Information.
Results
Identiﬁcation and characterization of hsa_circ_001783 via
circRNA–miRNA–breast cancer network
We performed our analysis according to the procedure
shown in Fig. 1a. Five algorithms, Targetscan, miRanda,
PITA, RNAhybrid, and RNA22 were used to predict
the potential bindings of miRNAs to the conserved
sequences of individual circRNAs (Supplementary
Table 1). We identiﬁed 923 circRNAs binding to 100
miRNAs through more than 37,000 potential interac-
tions. Screening ingenuity knowledge base, PubMed, and
Embase databases enables us to ﬁnd breast cancer-
associated miRNAs. After merging the data together, we
identiﬁed 594 breast cancer associated-circRNAs. Based
on our prior knowledge, ﬁve essential features including
self-renewal/apoptosis, chemotherapy resistance, differ-
entiation/proliferation, migration/invasion/metastasis,
and epithelia–mesenchymal transition (EMT) of breast
cancer cells were employed to rank the circRNAs
across the newly constructed circRNA–miRNA–breast
cancer database (Supplementary Table 2). We found
hsa_circ_001783 had the highest score among other 594
circRNAs (Fig. 1a; Supplementary Table 2). The ClueGo
analysis of its targeted miRNAs revealed hsa_-
circ_001783 was involved in enriched GO biological
processes such as cancer metastasis (e.g. cell migration
and cell–cell adhesion) and proliferation (e.g. regulation
of cell cycle and cell differentiation) (Fig. 1b).
Characterization of molecular structure of hsa_circ_001783
Apart from intergenic region, hsa_circ_001783 (chr9:
37086664–37121124) is partially derived from exon 2
in human endogenous Bornavirus-like nucleoprotein 3
(EBLN3), and exon 1 as well as intron 1 in zinc-ﬁnger
CCHC-type containing 7 (ZCCHC7; Fig. 1c). The
genomic sequence of hsa_circ_001783 is 34460nt. To
conﬁrm the circular characteristics of hsa_circ_001783,
we next digested total RNA with or without
Rnase R which has a 3′-5′exoribonuclease activity27.
Compared to the linear β-actin or GAPDH mRNAs,
hsa_circ_001783 was obviously resistant to Rnase R
(Fig. 1d). Since circRNAs generally lack poly A tail due
to its covalently closed looped structure, we then used
random primer or oligo DT primer alone to synthesize
cDNA. Poly A-tailed mRNAs, β-actin, and GAPDH
could be reversed to cDNA by either random primer or
oligo DT primer, while hsa_circ_001783 could only be
reversed by random primer only (Fig. 1e). These suggest
that hsa_circ_001783 possesses a loop structure. In
addition, we found 80% of hsa_circ_001783 located in
cytoplasm (Fig. 1f).
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High level of hsa_circ_001783 is correlated with poor
clinical outcomes in breast cancer patients
We further assessed the association between
hsa_circ_001783 expression and pathological character-
istics. Primary tumors from 136 breast cancer
patients were divided into two groups based on the
mean expression of hsa_circ_001783. We found that
hsa_circ_001783 expression was signiﬁcantly correlated
with tumor size (P < 0.001), lymph node (LN) status (P <
0.001), TNM stage (P < 0.001), ER status (P= 0.02), PR
status (P < 0.001), molecular subtype (TNBC vs. non-
TNBC, P < 0.001), and Ki-67 index (P= 0.008), but
not with age, menopause, HER2 status, and histological
grade (Table 1). In addition, RNA FISH showed that
hsa_circ_001783 was remarkably over-expressed in breast
cancer tissue compared to paired non-cancerous tissue
(see ﬁgure on previous page)
Fig. 1 Screening circRNA candidates in breast cancer and characteristics of hsa_circ_001783. a Workﬂow of screening circRNA candidates in
breast cancer. b The biological process ontology terms of hsa_circ_001783. c The genomic loci of hsa_circ_001783 and the Sanger sequence of
junction site of hsa_circ_001783 in two breast cancer cell lines: MDA-MB-231 and MDA-MB-468. d qPCR analysis of β-actin, GAPDH, and
hsa_circ_001783 (1783) after Rnase R treatment. ***P < 0.001 compared to no treatment group. e qPCR analysis of poly A-tailed mRNAs including β-
actin and GAPDH which can be synthesized to cDNA by using random primer or oligo DT primer alone and non-poly A-tailed RNA hsa_circ_001783
(1783) which cannot be reversed to cDNA by using oligo DT primer. ***P < 0.001 compared to the random primer. f qPCR analysis of hsa_circ_001783
in the cytoplasm and nuclear of which was separated by PARIS kit. β-Actin mRNA in cytoplasm and long non-coding RNA malat1 residing in nuclear
fraction were referred as quality controls of nuclear and cytoplasm fractions, respectively. Total RNA was total portion of the nuclear plus cytoplasm
and was referred as the control. ***P < 0.001 compared to the cytoplasm
Table 1 Clinical pathological variables of breast cancer patients
Variables Classiﬁer Low Hsa_circ_001783 High Hsa_circ_001783 Total P value RR
n= 98 n= 38 n= 136
Age ≤40 years 16 7 23 0.77 0.864
>40 years 82 31 113
Menopause Yes 63 27 90 0.454 0.733
No 35 11 46
Tumor size ≤2 cm 38 3 41 <0.001 7.389
>2 cm 60 35 95
LN status Negative 53 3 56 <0.001 13.741
Positive 45 35 80
TNM stage I 31 1 32 <0.001 17.119
II–III 67 37 104
Tumor grade I 9 2 11 0.727 1.82
II–III 89 36 125
ER Negative 22 19 41 0.002 0.289
Positive 76 19 95
PR Negative 19 19 38 <0.001 0.241
Positive 79 19 98
HER2 Negative 82 35 117 0.203 0.439
Positive 16 3 19
Molecular subtype TNBC 10 21 31 <0.001 0.092
Non-TNBC 88 17 105
Ki-67 ≤14% 45 8 53 0.008 3.184
>14% 53 30 83
LN lymph node, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RR relative risk, TNBC triple-negative breast cancer
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(Fig. 2a, b). Furthermore, this circRNA was upregulated in
ER-PR-HER2- (triple negative, TN) subtype compared to
the luminal and HER2 ampliﬁcation (HER2+) subtypes
(Fig. 2a). Being consistent with FISH results, qPCR
showed that hsa_circ_001783 was upregulated by 2.64-
fold high (P < 0.0001) in tumor samples of triple-negative
breast cancer (TNBC, Fig. 2c). Since hsa_circ_001783 was
upregulated in tumors with higher proliferation potential,
we further examined the relationship between the hsa_-
circ_001783 expression and Ki-67 proliferation index. We
found that hsa_circ_001783 was positively correlated with
the Ki-67 level in breast tumors (P= 0.009; Fig. 2d, e).
Our Kaplan–Meier analysis further revealed that patients
with higher level of hsa_circ_001783 were more likely to
develop disease recurrence and had poor disease-free
survival (P < 0.001; Fig. 2f). Multivariate analysis showed
that the expression level of hsa_circ_001783 was an
independent factor for predicting the prognosis of breast
cancer patients (hazard ratio, HR: 9.114; 95% conﬁdence
interval, 95% CI: 2.428–34.206, P= 0.001; Supplementary
Table 3).
Construction of co-expression network, GO, and KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway
analysis
We quantiﬁed the expression levels of hsa_circ_001783
in different breast cancer cell lines, analyzed the genes
correlated with hsa_circ_001783 expression, and per-
formed GO analysis to predict the potential functions.
The basal level of hsa_circ_001783 was much higher in
breast cancer cell lines than non-tumorigenesis breast
mammary cell line MCF-10A (Fig. 3a). Consistent with
the level of hsa_circ_001783 in breast cancer samples, we
found that hsa_circ_001783 was 2.5–3-folds higher in
TNBC cell lines (MDA-MB-231, MDA-MB-468, and
BT-549) than luminal and HER2-overexpression cell line
breast cancer tissue
ER-PR-HER2+
Adjacent non-
cancerous tissue
1783
A
E
breast cancer tissueB
C
P=0.008
pe
rc
en
to
fK
i-6
7
(%
) 100
80
60
40
20
0
low 1783 high 1783
3
fold change = 2.64
p < 0.0001
2
1
0
luminal/HER2+ TNBC
re
la
tiv
e
fo
ld
ER+PR+HER2+ER+PR+HER2- ER-PR-HER2-
ER-PR-HER2+ER+PR+HER2+ER+PR+HER2- ER-PR-HER2-
4
5
3
2
aside (paired) tumor (paired)
***
1
0
re
la
tiv
e
fo
ld
K
i-6
7
D
FS
(%
)
100
80
60
40
20
0
0 20 40 60 80
Follow-up time (months)
low 1783
high 1783 P < 0.001
n=98
n=38
F
D
Fig. 2 Hsa_circ_001783 is up-regulated and correlated with poor clinical outcomes in breast cancer patients. a The cellular location and
relative expression of hsa_circ_001783 in breast cancer tissue and adjacent non-cancerous tissue. The nuclear was stained with DAPI for blue color
and hsa_circ_001783 was stained for red color. Scale bar, 20 μm. b The level of hsa_circ_001783 in breast cancer tissue compared to paired non-
cancerous tissue (n= 18) analyzed by FISH. ***P < 0.001 compared to the level of hsa_circ_001783 in paired breast cancer tissue. c The expression of
hsa_circ_001783 in frozen fresh breast cancer samples analyzed by qPCR (TNBC n= 11, Luminal/HER2+ n= 39). d The corresponding Ki-67 staining
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(BT-474, MCF-7, T47D, and SK-BR-3) (Fig. 3a). To fur-
ther predict the potential function of hsa_circ_001783,
we analyzed the positively co-expressed genes of hsa_-
circ_001783 in MDA-MB-231, MDA-MB-468, and BT-
549 with the Pearson correlation co-efﬁciency cut-off
value >0.1 (GSE41313; Supplementary Tables 3 and 4).
Based on the binding sites of miRNAs in the positively
co-expressed genes and the hsa_circ_001783 predicted
targeting miRNAs, we constructed a hsa_circ_001783–
miRNA–mRNA network (Fig. 3b). We then employed
KEGG pathway and GO to analyze the biological func-
tions of genes in this hsa_circ_001783–miRNA–mRNA
network, assuming that the hsa_circ_001783 may
have molecular interactions with these genes, or could
be involved in regulating biological functions of these
genes. Hsa_circ_001783-correlated genes were enriched
in cancer-associated KEGG pathways including PI3K–Akt
signaling pathway, transcriptional misregulation in
cancer, microRNA in cancer, and focal adhesion (Fig. 3c).
Hsa_circ_001783 were signiﬁcantly correlated with genes
in the biological process of genes ontology, including IL6,
ETS1, E2F7, SIX1, ZEB1, COL4A1, COL3A1, and
COL1A1, which were enriched in regulation of tran-
scription, regulation of cell proliferation, collagen cata-
bolic process, and cell migration. In the analysis of cell
component ontology, hsa_circ_001783-correlated genes,
such as IL6, LMO7, ZEB1, ETS1, SIX1 and MSN, were
mainly enriched in cytoplasm, transcription factor com-
plex, extracellular matrix, and focal adhesion, respectively.
In the ontology analysis of molecular function,
hsa_circ_001783-correlated genes (including E2F7,
COL3A1, ZEB1, MSN, RUNX2, IL6, COL4A2, COL4A1,
TGFBR2, CLIC4, ETS1, SIX1, CYBRD1, TGFBR3,
MAPRE2 and COL1A1) were enriched in protein binding,
transcriptional factor binding, SMAD binding, and
ECM structural constituent, respectively (Fig. 3d). Taken
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together, the KEGG and GO analysis suggest that
hsa_circ_001783-correlated genes are associated with
cancer growth and metastasis (Table 2).
Knockdown of hsa_circ_001783 inhibits the progression of
breast cancer cells
Our clinical data showed the correlations between
hsa_circ_001783 expression level and breast cancer pro-
gression, and the GO analysis indicated hsa_circ_001783-
correlated genes played profound roles in malignancy. We
thus ﬁne-tuned the expression of hsa_circ_001783 and
monitored its cellular effects on two TNBC cell lines
(MDA-MB-231 and MDA-MB-468) that highly expressed
hsa_circ_001783 (Fig. 3a). Transfection of siRNAs that
speciﬁcally targeted junction site of hsa_circ_001783
reduced its expression by 40–50% without any
effect on EBLN3 or ZCCHC7 (Fig. 4a, b). Knockdown of
hsa_circ_001783 signiﬁcantly inhibited cell variability of
MDA-MB-231 and MDA-MB-468 in day 4 after siRNA
transfection (Fig. 4c). In addition, the EdU assay showed
that downregulation of hsa_circ_001783 impaired the
proliferation of MDA-MB-231 and MDA-MB-468, which
was in consistent with the data in CCK8 assay (Fig. 4d).
Colony formation ability was also disrupted after hsa_-
circ_001783 knockdown (Fig. 4e).
Our clinical data showed that breast cancer patients
with high expression of hsa_circ_001783 suffered from
more metastases (Fig. 2f). As metastasis begins with pri-
mary cancer cells acquiring migration and invasion abil-
ities28,29, we next analyzed the effects of hsa_circ_001783
on metastatic ability of breast cancer cells in vitro.
We used Boyden chamber coated with or without
matrigel to evaluate the invasion and migration ability of
breast cancer cells, respectively. After knockdown of
hsa_circ_001783, migration ability and invasion capacity
of the MDA-MB-231 and MDA-MB-468 were
signiﬁcantly decreased (Figs. 4f, g). Of noted, the pro-
liferative status of these two cell lines was not signiﬁcantly
altered at the migration or invasion time point, suggesting
that hsa_circ_001783 played a role in regulating the
metastasis of breast cancer cells.
Identiﬁcation of hsa_circ_001783-correlated miRNAs
Data mining of GEO datasets (GSE28969 and
GSE40086) revealed that 19 miRNAs were higher and 20
miRNAs were lower in TNBC (MDA-MB-231, MDA-
MB-468, and BT-549) than luminal/HER2+ cell lines
(MCF-7, SK-BR-3, T47D, and BT-474; Fig. 5a, b; Sup-
plementary Table 3). As hsa_circ_001783 expressed
higher in TNBC than luminal/HER2+ cell lines (Fig. 3a),
this suggests that these 19 miRNAs from GSE28969 and
GSE40086 positively correlate with hsa_circ_001783 while
other 20 miRNAs negatively correlate with hsa_-
circ_001783. Among these miRNAs, only miR-200c-3p
was predicted as the target of hsa_circ_001783 (Fig. 5c).
Hsa_circ_001783 contributes to breast cancer progression
via sponging miR-200c-3p
To conﬁrm the miR-200c-3p is the sponging target of
hsa_circ_001783, we ﬁrst calculated the number of
potential binding sites between hsa_circ_001783 con-
served sequences and miR-200c-3p by RNAhybrid. We
found 18 bindings between them with the free energy
<−20 kcal/mol (Supplementary Table 5). The one with
Table 2 Multivariate Cox analysis of variables considered for disease-free survival rates of breast cancer patients
Variables Category Multivariate
HR 95% CI lower 95% CI upper P value
Age >40 vs. ≤40 years 0.645 0.218 1.91 0.429
Tumor size >2 vs. ≤2 cm 1.743 0.402 7.548 0.458
LN status Positive vs. Negative 3.435 0.723 16.324 0.121
TNM stage Stage II–III vs. I 0.387 0.065 2.313 0.298
Grade Grade II–III vs. I 0.105 0.018 0.613 0.012
ER status Positive vs. Negative 0.767 0.141 4.182 0.759
PR status Positive vs. Negative 0.258 0.044 1.528 0.135
HER2 status Positive vs. Negative 1.451 0.203 10.381 0.711
Ki-67 status >14% vs. ≤14% 3.418 0.823 14.193 0.091
Molecular subtype TNBC vs. non-TNBC 4.459 0.48 41.439 0.189
Hsa_circ_001783 High vs. ≤Low 9.114 2.428 34.206 0.001
LN lymph node, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, CI conﬁdence interval, TNBC triple-
negative breast cancer
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the lowest free energy was shown in Fig. 6a. To further
verify whether the miRNA bound to the conserved region
of hsa_circ_001783, we analyzed three PAR-CLIP datasets
of AGO1 and AGO2 (GSE28865, GSE43573, and
GSE21918). The result showed a high density and
degree of AGO1/2 occupancy within the conserved
region of hsa_circ_001783 (Fig. 6a). To validate this result,
we conducted AGO2 RIP and found that endogenous
hsa_circ_001783 could be speciﬁcally pulled down
by anti-AGO2 antibody (Fig. 6b). This suggests that
hsa_circ_001783 acts as a miRNA-binding partner. By
using probe targeting hsa_circ_001783 junction site, we
found that hsa_circ_001783 and miR-200c-3p were
signiﬁcantly more abundant compared with the control
(Fig. 6c). Moreover, according to a previously described
method24–26 we conducted a luciferase assay by
co-transfection of miR-200c-3p mimics and inhibitor with
luciferase reporter into MDA-MB-231 and MDA-MB-
468, respectively. Transfection of miR-200c-3p mimics
reduced the luciferase reporter activity by 40%, while miR-
200c-3p inhibitor promote the luciferase reporter activity
by at least 1.4-fold (Fig. 6d). Of note, hsa_circ_001783
co-localized with miR-200c-3p in the cytoplasm of
MDA-MB-231 cells (Fig. 6e). Besides, knockdown of
hsa_circ_001783 enhanced miR-200c-3p expression and
suppressed miR-200c-3p targeted genes: ZEB1, ZEB2, and
(see ﬁgure on previous page)
Fig. 4 Effect of hsa_circ_001783 on MDA-MB-231 and MDA-MB-468 progression. a Schematic representation of the siRNA sequences
speciﬁcally targeted the junction site of hsa_circ_001783. b qPCR analysis of the transfection efﬁcacy and off-target effects of siRNA on EBLN3 and
ZCCHC7 expression in MDA-MB-231 and MDA-MB-468 after 24 h transfection. **P < 0.01 compared to mock; *P < 0.05 compared to mock. c The
proliferation status of MDA-MB-231 and MDA-MB-468 determined by CCK-8 assay after hsa_circ_001783 knockdown. OD optical density. **P < 0.01
compared to mock. d EdU assay to determine DNA synthesis of MDA-MB-231 and MDA-MB-468 transfected with siRNAs. All the data are shown as
the mean ± SD; *P < 0.05 compared to mock. Scale bar, 100 μm. e Colony formation ability of MDA-MB-231 and MDA-MB-468 transfected with siRNA.
All the data are shown as the mean ± SD; *P < 0.05 compared to mock. f The representative images of migrated MDA-MB-231 and MDA-MB-468 after
hsa_circ_001783 knockdown. All the data are shown as the mean ± SD; *P < 0.05, compared to mock. Scale bar, 100 μm. g The representative images
of invaded MDA-MB-231 and MDA-MB-468 after hsa_circ_001783 knockdown. All the data are shown as the mean ± SD; *P < 0.05, compared to
mock. Scale bar, 100 μm
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ETS1 (Fig. 6f; Supplementary Figure 1A). The negative
correlation between hsa_circ_001783 and miR-200c-3p
and positive correlation between hsa_circ_001783 and
ZEB1, ZEB2, and ETS1 were further observed in the
tumor tissues from breast cancer patients (Fig. 6g).
Transfection of miR-200c-3p inhibitor (miR-200c
inhibitor) reduced the level of miR-200c-3p and
enhanced migration and invasion of MDA-MB-231
(Supplementary Figure 1B). And co-transfection of
hsa_circ_001783 siRNAs and miR-200c-3p inhibitor in
MDA-MB-231 and MDA-MB-468 cells rescued cell pro-
liferation and colony formation (Fig. 6h, i; Supplementary
Figure 1C, D), migration and invasion (Fig. 6j, k; Sup-
plementary Figure 1E, F). Together, these data suggest
hsa_circ_001783 regulates breast cancer progression via
sponging miR-200c-3p.
Discussion
To the best of our knowledge, this is the ﬁrst study that
systematically analyzed the circular RNAs in breast cancer
based on their characteristic in sponging disease speciﬁc
miRNAs. By combination of our systematical pipeline,
experimental technologies in vitro and ex vivo, we
explored the role of circRNAs in progression of breast
cancer via sponging miRNAs. Among all the breast
cancer-associated circRNAs, hsa_circ_001783 was the one
with the highest ranked score. Higher expression of
hsa_circ_001783 associated with higher tumor burden
and poorer prognosis of breast cancer. More importantly,
hsa_circ_001783 regulated proliferation and metastasis of
breast cancer cells via sponging miR-200c-3p.
Recently, circRNAs have been proved to act as miRNA
sponges. Unlike other linear competitive endogenous
RNA, circRNAs is more stable due to the covalently
closed looped structure. The half-life of most circRNAs is
longer than that of corresponding linear RNAs4. Previous
studies focused on screening of the differentially expres-
sed circRNAs rather than the circRNAs with sponging
potential. However, if we merely screen circRNAs just
based on the fold changes, it might result in ignoring
some circRNAs which have more potent to sponge miR-
NAs. Besides, circRNAs is beyond miRNAs sponges as
they exert their regulation role in coding peptides, inter-
action with proteins, and regulation on transcription30,31,
which suggests screening differentially expressed cir-
cRNAs might lead to an uncertain direction.
Of note, we used ﬁve essential functional features
of breast cancer to rank the circRNAs across the con-
structed circRNA–miRNA–breast cancer database. This
strengthened the association between hsa_circ_001783
and breast cancer, although the total classes that
hsa_circ_001783 sponged are not the best; for instance,
hsa_circ_001851 harbors 13 classes of miRNA. Besides,
we have uncovered that hsa_circ_001783 contributes to
breast cancer progression via sponging miR-200c-3p and
facilitates its prediction of clinical outcomes. Thus, the
combination of high throughput computation, experi-
mental technologies in vitro and clinical investigation
turns out to be another efﬁcient way to screen the “cir-
cular sponges” and potentially serves as a powerful
approach to explore the novel predictors of clinical
outcomes.
MiR-200c-3p has been reported to confer the progres-
sion abilities to breast cancer cells and exerts peculiar
regulation roles in cancer proliferation, growth, migration,
and invasion processes32–34. Interestingly, when we
knocked down the expression of hsa_circ_001783, the
proliferation, colony formation, and invasion abilities of
breast cancer cells were suppressed, accompanied with
the reduced expression of the miR-200c-3p targeted genes
such as ZEB1/2 (refs. 32,33) and ETS1 (refs. 34,35), which
are related to breast cancer proliferation and metastasis.
Consistent with these in vitro ﬁndings, in clinical speci-
mens, the expression level of ZEB1/2 and ETS1 is
highly positively correlated with the expression of
hsa_circ_001783. It is acknowledged that circRNAs
(see ﬁgure on previous page)
Fig. 6 Hsa_circ_001783 serves as sponge for miR-200c-3p. a Examples of the potential bindings between hsa_circ_001783 conserved sequence
and miR-200c-3p. Hsa_circ_001783 conserved locus is densely bound by AGO1 (red) and AGO2 (red). b AGO2 RNA-binding protein
immunoprecipitation. 1783 is referred as hsa_circ_001783. All data are shown as the mean ± SD. ***P < 0.001 compared to IgG. c circRNA pull-down
assay. 1783 is referred as hsa_circ_001783. **P < 0.01 compared to negative control (NC) probe. d Luciferase assay of MDA-MB-231 and MDA-MB-468
co-transfected with luciferase reporter containing hsa_circ_001783 conserved sequences and miR-200c-3p mimic or miR-200c-3p inhibitor. NC
represents mimic negative control and inhibitor negative control. All data are shown as the mean ± SD. **P < 0.01 compared to negative control. e
RNA ﬂuorescence in situ hybridization for co-localization of hsa_circ_001783 and miR-200c-3p in MDA-MB-231. Scale bar 10 μm. f The expression of
hsa_circ_001783 and miR-200c-3p mRNA targets: ZEB1, ZEB2, and ETS1 after hsa_circ_001783 knockdown. g qPCR analysis of the expression of
hsa_circ_001783, miR-200c-3p, and miR-200c-3p mRNA targets: ZEB1, ZEB2, and ETS1 in breast cancer clinical specimens. h The proliferation status of
MDA-MB-231 after siRNA transfection or miR-200c-3p inhibitor co-transfection determined by CCK-8. OD optical density. All data are shown as the
mean ± SD; **P < 0.01 compared to mock. i Colony formation ability of MDA-MB-231 after siRNA transfection or miR-200c-3p inhibitor co-transfection.
j The representative images of migrated and invaded MDA-MB-231 after siRNA transfection or miR-200c-3p inhibitor co-transfection. Scale bar, 100
μm. k The migration and invasion abilities of MDA-MB-231 after hsa_circ_001783 knockdown or miR-200c-3p inhibitor co-transfection. All the data
are shown as the mean ± SD; *P < 0.05, compared to mock
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sponge miRNAs and inhibit the function of miRNAs,
which in turn up-regulates the mRNAs11,13,16. According
to our data, we conﬁrm that hsa_circ_001783 regulates
ZEB1/2 and ETS1 via sponging miR-200c-3p, which is
consistent with other published articles. For instance,
after circHIPK3 knockdown, miR-124 is released and the
miR-124 targeting genes such as IL6R and DLX2 are
down-regulated13. CDR1as can harbor miR-7 massively
and Fos, Klf4, and Nr4a3 targeted by miR-7 can be enri-
ched in CDR1as knockout mice11,16. Therefore, our study
indicates that hsa_circ_001783 can sponge miR-200c-3p
and up-regulate miR-200c-3p targeting genes.
Conclusion
In summary, we have proposed a comprehensive
method to systematically screen breast cancer speciﬁc
circular RNAs through integrating an in silico pipeline
with in vitro and ex vivo techniques. We highlighted that
hsa_circ_001783 as a novel prognostic marker for breast
cancer and uncovered its new mechanism in regulat-
ing cancer proliferation and metastasis via sponging miR-
200c-3p. Thus, this circular RNA might be a potential
therapeutic target for breast cancer treatment.
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